These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36347174)

  • 1. Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States.
    Qi CZ; Hughes T; Gelinas D; Li Y; Goyal A; Brauer E; Bhuwalka A; Sato M; Jadhav S; Phillips G
    J Neurol Sci; 2022 Dec; 443():120480. PubMed ID: 36347174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States.
    Parthan A; Royston M; Thanataveerat A; East EL; Parzynski CS; Habib AA
    Muscle Nerve; 2024 Feb; 69(2):157-165. PubMed ID: 38018505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment.
    Ting A; Story T; Lecomte C; Estrin A; Syed S; Lee E
    J Neurol Sci; 2023 Feb; 445():120531. PubMed ID: 36634582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
    Phillips G; Abreu C; Goyal A; Li Y; Whangbo A; Gelinas D; Brauer E; Bhattacharya S
    Front Neurol; 2021; 12():809999. PubMed ID: 35115997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.
    Sorgun MH; Sener HO; Yucesan C; Yucemen N
    Neurol Sci; 2014 Jun; 35(6):891-6. PubMed ID: 24399309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in myasthenia gravis: A United States health claims analysis.
    Mahic M; Bozorg A; Rudnik J; Zaremba P; Scowcroft A
    Muscle Nerve; 2023 Apr; 67(4):297-305. PubMed ID: 36721910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka KV
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    Wilf-Yarkoni A; Lotan I; Steiner I; Hellmann MA
    J Neurol; 2021 Oct; 268(10):3871-3877. PubMed ID: 33829320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.
    Yanagihashi M; Okamoto R; Morioka H; Sawada M; Matsumoto S; Ikeda T; Kano O
    BMC Neurol; 2020 Aug; 20(1):319. PubMed ID: 32859168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
    Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis.
    Huang CS; Hsu HS; Kao KP; Huang MH; Huang BS
    Acta Neurol Scand; 2003 Aug; 108(2):136-8. PubMed ID: 12859292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
    Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
    Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy.
    Gamez J; Salvado M; Casellas M; Manrique S; Castillo F
    J Neurol Sci; 2017 Dec; 383():118-122. PubMed ID: 29246598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose intravenous immunoglobulin therapy in myasthenia gravis: a case report.
    Chu CC; Huang CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Mar; 57(3):232-5. PubMed ID: 8935232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?
    Gwathmey KG; Ding H; Hehir M; Silvestri N
    Muscle Nerve; 2024 Apr; 69(4):389-396. PubMed ID: 38308492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.